公开(公告)号：WO2019105936A1

公开(公告)日：2019-06-06

申请号：PCT/EP2018/082715

申请日：2018-11-27

Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC)

Inventor： GUTIÉRREZ FERNÁNDEZ, Diana ,  MARTÍNEZ FERNÁNDEZ, Beatriz ,  GARCÍA SUÁREZ, Pilar ,  RODRÍGUEZ GONZÁLEZ, Ana ,  RODRÍGUEZ-RUBIO, Lorena ,  LAVIGNE, Rob

IPC: A61K38/47 ,  A61K38/54 ,  C12N9/14 ,  C12N9/24

CPC classification number: C12N9/14 ,  A61K38/47 ,  A61K38/54 ,  C07K2319/00 ,  C12N9/2497

Abstract: The present invention relates to a chimeric protein comprising the CHAP catalytic domain of the endolysin LysRODI from phage PhiIPLA-RODI and the SH3b cell wall binding domain of the endolysin LysH5 from phage phiIPLA88. This chimeric protein shows an improved lytic activity again Staphylococcus sp. and a higher stability than the other endolysins of the state of the art. The invention also relates to a polynucleotide encoding the chimeric protein, and the host cell or the composition comprising the chimeric protein or the polynucleotide encoding thereof, as well as its use for the treatmentand/or preventionof an infection of Staphylococcus sp, and/or for removing, inhibiting and/or preventing Staphylococcus sp. biofilm formation on abiotic surfaces, or for removing and/or preventing the Staphylococcus sp. contamination of foods and/or abiotic surfaces.

公开(公告)号：WO2017070632A3

公开(公告)日：2017-06-08

申请号：PCT/US2016058344

申请日：2016-10-22

Applicant: HARVARD COLLEGE

Inventor： LIU DAVID R ,  KOMOR ALEXIS CHRISTINE ,  REES HOLLY A ,  KIM YONGJOO

IPC: C07K14/32 ,  C12N9/22 ,  C12N9/78 ,  C12N15/10 ,  C12N15/90

CPC classification number: C12N9/22 ,  C07K14/32 ,  C07K2319/00 ,  C07K2319/09 ,  C07K2319/80 ,  C12N9/2497 ,  C12N9/78 ,  C12N15/907 ,  C12Y305/04005

Abstract: Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing proteins or domains, are provided.

Abstract translation: 本公开的一些方面提供可用于核酸的定向编辑的策略，系统，试剂，方法和试剂盒，包括编辑例如人基因组内的细胞或受试者基因组内的单个位点。 在一些实施方案中，提供了Cas9的融合蛋白和核酸编辑蛋白或蛋白结构域，例如脱氨酶结构域。 在一些实施方案中，提供了用于靶向核酸编辑的方法。 在一些实施方案中，提供用于产生靶向核酸编辑蛋白的试剂和试剂盒，例如Cas9的融合蛋白和核酸编辑蛋白或结构域。

公开(公告)号：WO2015191764A1

公开(公告)日：2015-12-17

申请号：PCT/US2015/035179

申请日：2015-06-10

Applicant: MOLECULAR TEMPLATES, INC.

Inventor： POMA, Eric ,  WILLERT, Erin ,  HIGGINS, Jack ,  KIM, Jason

IPC: C07K14/195 ,  C07K14/245 ,  C07K14/25 ,  C12N9/10 ,  C12N9/24 ,  C12N15/62

CPC classification number: C12N9/2497 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/245 ,  C07K14/25 ,  C07K14/70539 ,  C07K14/70596 ,  C07K16/085 ,  C07K16/088 ,  C07K16/1063 ,  C07K16/18 ,  C07K16/20 ,  C07K16/286 ,  C07K16/2866 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/33 ,  C07K2319/55 ,  C07K2319/74 ,  C12N9/1077 ,  C12Y204/02036 ,  C12Y302/02022

Abstract: The present invention provides protease-cleavage resistant molecules comprising Shiga toxin effector polypeptides capable of exhibiting potent, Shiga toxin functions ( e.g . subcellular routing and cytotoxicity). The present invention also provides protease-cleavage resistant, cell-targeted molecules for targeting specific cell types, e.g ., infected or malignant cells. Certain molecules of present invention are cytotoxic, and certain cell-targeted molecules of present invention may be used for the targeted killing of specific cell types and treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections. Certain cell-targeted molecules of the invention exhibit improved, in vivo tolerability as compared to related cell-targeted molecules comprising protease-cleavage sensitive, wild-type, Shiga toxin effector polypeptides. The cell-targeted molecules of the invention can deliver additional materials, such as, e.g ., antigens, cytotoxic agents, and detection-promoting agents, into interiors of target cells.

Abstract translation: 本发明提供蛋白酶切割抗性分子，其包括能显示有效的志贺毒素功能（例如亚细胞定位和细胞毒性）的志贺毒素效应子多肽。 本发明还提供用于靶向特定细胞类型（例如感染或恶性细胞）的蛋白酶切割抗性的细胞靶向分子。 本发明的某些分子是细胞毒性的，并且本发明的某些细胞靶向分子可用于靶向特异性细胞类型的杀伤和各种疾病，病症和病症的治疗，包括癌症，肿瘤，生长异常，免疫 病症和微生物感染。 与包含蛋白酶切割敏感的野生型志贺毒素效应物多肽的相关细胞靶向分子相比，本发明的某些细胞靶向分子表现出改进的体内耐受性。 本发明的细胞靶向分子可以向靶细胞的内部递送另外的材料，例如抗原，细胞毒性剂和检测促进剂。

公开(公告)号：WO2014003537A1

公开(公告)日：2014-01-03

申请号：PCT/MY2013/000115

申请日：2013-06-25

Applicant: BIOVALENCE SDN. BHD.

Inventor： SEKARAN, Shamala Devi K C ,  ROTHAN, Hussin A. ,  UNG, Eng Huan ,  ABU BAKAR, Ag. Muhammad Sagaf

IPC: C07K19/00 ,  A61K38/00 ,  A61P35/00

CPC classification number: A61K38/16 ,  A61K38/02 ,  A61K38/10 ,  C07K14/4723 ,  C07K2319/00 ,  C12N9/2497

Abstract: Use of fusion protein comprising at least one polypeptide B, comprising Type 1 Ribosome Inactivating Protein, and at least one C having anticancer properties in the manufacture of a medicament for treating cancer in a subject in need thereof.

Abstract translation: 包含至少一种包含1型核糖体灭活蛋白的多肽B和至少一种具有抗癌特性的C的融合蛋白在制备用于治疗有需要的受试者中的癌症的药物中的应用。

公开(公告)号：WO2013123223A1

公开(公告)日：2013-08-22

申请号：PCT/US2013/026183

申请日：2013-02-14

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： GARRIDO, Daniel ,  GERMAN, J. Bruce ,  LEBRILLA, Carlito B. ,  MILLS, David A.

IPC: C07K7/06 ,  A61K38/08 ,  C12N15/52 ,  A23L1/29

CPC classification number: A61K38/47 ,  A23C9/1216 ,  A23L2/52 ,  A23L33/195 ,  A61K31/715 ,  A61K35/741 ,  A61K38/00 ,  A61K38/40 ,  C07K14/79 ,  C12N9/2402 ,  C12N9/2497 ,  C12P19/04 ,  C12P21/005 ,  C12Y302/01096 ,  Y02P20/52 ,  A61K2300/00

Abstract: Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.

Abstract translation: 本文提供了去糖基化酶，其从N-糖基化蛋白质中除去宽范围的N-聚糖。 还提供了重组产生和表达去糖基化酶的方法。 目前描述的去糖基化酶可用于产生用于表征的游离聚糖，以及益生元和免疫刺激用途。 此外，目前描述的去糖基化酶可以用于产生去糖基化的蛋白质用于表征，以改善消化和降低免疫原性。

公开(公告)号：WO2013085624A1

公开(公告)日：2013-06-13

申请号：PCT/US2012/060441

申请日：2012-10-16

Applicant: CHEN, Haifeng ,  VIROVEK, INC.

Inventor： CHEN, Haifeng

IPC: C12N15/31 ,  C12N15/113 ,  C12N15/79 ,  C12N15/64 ,  C12N5/10 ,  A61P35/00 ,  A61K31/7088 ,  A61K35/76

CPC classification number: C12N15/86 ,  A61K31/7088 ,  A61K48/00 ,  C07K14/21 ,  C07K14/34 ,  C12N9/22 ,  C12N9/2497 ,  C12N2710/14043 ,  C12N2710/14052 ,  C12N2750/14143 ,  C12N2750/14152 ,  C12N2799/026 ,  C12N2830/42 ,  C12N2840/005 ,  C12N2840/102 ,  C12N2840/44 ,  C12N2840/85

Abstract: The present disclosure describes nucleic acids, and viruses comprising such nucleic acids, for growing a toxic gene in an insect cell. These nucleic acids comprise a sequence encoding a toxic polypeptide, and an intron that interrupts the sequence, whereby the intron is spliced in mammalian cells but not in insect cells. Infection of mammalian cells but not insect cells with the nucleic acids or viruses can lead to expression of toxic levels of the toxic polypeptide in mammalian cells but not in insect cells. Viruses, such as an AAV or a baculovirus comprising a nucleic acid can be grown in insect cell lines in vitro and can be administered to a subject in need of therapy, such as a subject in need of cancer therapy.

Abstract translation: 本公开描述了用于在昆虫细胞中生长毒性基因的核酸和包含此类核酸的病毒。 这些核酸包含编码毒性多肽的序列和中断该序列的内含子，由此内含子在哺乳动物细胞中剪接而不在昆虫细胞中剪接。 哺乳动物细胞而不是昆虫细胞与核酸或病毒的感染可导致在哺乳动物细胞中毒性水平的毒性水平的表达，但不能在昆虫细胞中表达。 病毒如AAV或包含核酸的杆状病毒可以在昆虫细胞系中体外生长，并且可以施用于需要治疗的受试者，例如需要癌症治疗的受试者。

公开(公告)号：WO2012096926A3

公开(公告)日：2012-10-26

申请号：PCT/US2012020731

申请日：2012-01-10

Applicant: HARVARD COLLEGE ,  COLLIER ROBERT J ,  PENTELUTE BRAD L

Inventor： COLLIER ROBERT J ,  PENTELUTE BRAD L

IPC: A61K47/48 ,  A61K9/08 ,  A61K9/10 ,  A61K38/08 ,  A61K38/16 ,  A61P31/00

CPC classification number: C12N9/52 ,  A61K38/00 ,  C07K14/195 ,  C07K16/46 ,  C07K2319/10 ,  C07K2319/50 ,  C07K2319/55 ,  C12N9/1048 ,  C12N9/2497

Abstract: The invention provides compositions and methods for delivering a bioactive moiety comprising at least one non-natural component into a cell cytosol of an eukaryotic cell. The bioactive moiety is linked to an A component of a bacterial toxin, a functional wild-type or modified fragment thereof, or an A component surrogate or mimetic. For delivery, the cell is contacted with the linked bioactive moiety and a corresponding B component of the bacterial toxin or a functional fragment thereof.

Abstract translation: 本发明提供了将包含至少一种非天然成分的生物活性部分递送到真核细胞的细胞质溶胶中的组合物和方法。 生物活性部分连接到细菌毒素的A成分，其功能性野生型或修饰片段，或A组分替代物或模拟物。 为了递送，细胞与所连接的生物活性部分和细菌毒素的相应B组分或其功能片段接触。

公开(公告)号：WO2012061910A3

公开(公告)日：2012-09-13

申请号：PCT/BR2011000411

申请日：2011-11-08

Applicant: UNIV RIO DE JANEIRO ,  UNIV FED DE SAO PAULO ,  UNIV SAO PAULO ,  PALATNIK DE SOUZA CLARISA BEATRIZ ,  MARTINS RODRIGUES MAURICIO ,  DA SILVA SOARES IRENE ,  PALATNIK MARCOS ,  DIRLEI NICO

Inventor： PALATNIK DE SOUZA CLARISA BEATRIZ ,  MARTINS RODRIGUES MAURICIO ,  DA SILVA SOARES IRENE ,  PALATNIK MARCOS ,  DIRLEI NICO

IPC: C07K14/44 ,  A61K38/50 ,  A61K39/008 ,  A61P33/00 ,  C12N9/14 ,  C12N15/55 ,  C12R1/90

CPC classification number: C12N9/2497 ,  A61K38/00 ,  C07K14/44

Abstract: The present innovation relates to the identification of the main sequences of the protein nucleoside hydrolase from Leishmania (L) donovani, to be included in a recombinant, DNA or synthetic vaccine to protect and cross-protect against leishmanioses. It also relates to the identification of the main epitopes that react with antibodies to be used in the immunodiagnosis of leishmanioses, and to the use thereof to give cross-protection against other micro-organisms having a sequence in common in the nucleoside hydrolases thereof.

Abstract translation: 本发明涉及鉴定来自杜氏利什曼原虫（Leishmania（L）donovani的蛋白质核苷水解酶的主要序列，以包含在重组，DNA或合成疫苗中以保护和交叉防护利什曼病。 本发明还涉及鉴定与在利什曼​​病的免疫诊断中使用的抗体反应的主要表位，以及其用于对其核苷水解酶中具有共同序列的其他微生物提供交叉保护。

公开(公告)号：WO2012007728A3

公开(公告)日：2012-09-07

申请号：PCT/GB2011001074

申请日：2011-07-18

Applicant: SECR DEFENCE ,  PHILLIPS GARY JOHN ,  GRIFFITHS GARETH DAVID ,  CORK LUCY JANE ,  WHITFIELD DAVID

Inventor： PHILLIPS GARY JOHN ,  GRIFFITHS GARETH DAVID ,  CORK LUCY JANE ,  WHITFIELD DAVID

IPC: A61K39/00

CPC classification number: C07K14/415 ,  A61K38/00 ,  A61K39/39 ,  A61K2039/55544 ,  C07K14/21 ,  C07K14/235 ,  C07K14/25 ,  C07K14/28 ,  C07K14/31 ,  C07K14/33 ,  C07K14/46 ,  C07K16/1282 ,  C07K16/16 ,  C12N9/2497 ,  C12N9/52 ,  C12Y302/02022

Abstract: The present invention relates to the use of toxoids prepared using a-dicarbonyl toxoiding reagents such as glyoxal, butanedione and phenylglyoxal. The toxoids may be prepared with low concentrations of toxoiding reagent and in short periods of time, often in as few as 24 hours, making the toxoiding reagents particularly advantageous when compared with traditional formaldehyde toxoiding. Toxoids prepared using dicarbonyl reagents such as phenylglyoxal are described and claimed as are pharmaceutical and vaccine compositions comprising the toxoids, methods of treatment using such compositions and antibodies generated by immunisation with the toxoid and methods of treatment using the antibodies so prepared or fragments of such antibodies.

Abstract translation: 本发明涉及使用二羰基类毒素试剂如乙二醛，丁二酮和苯乙醛制备的类毒素。 类毒素可以用低浓度的类毒素试剂制备，并且在短时间内，通常在短短24小时内，使得类毒素试剂与传统甲醛类毒素相比尤其有利。 使用二羰基试剂如苯基乙二醛制备的毒素被描述和要求保护，包括含有类毒素的药物和疫苗组合物，使用这种组合物的治疗方法和用类毒素免疫产生的抗体以及使用所制备的抗体或这种抗体的片段的治疗方法 。

公开(公告)号：WO2012103165A2

公开(公告)日：2012-08-02

申请号：PCT/US2012/022471

申请日：2012-01-25

Applicant: KOLLTAN PHARMACEUTICALS, INC. ,  HADARI, Yaron ,  MANDEL-BAUSCH, Elizabeth, M. ,  RADKE, Susanne ,  SCHLESSINGER, Joseph ,  SUZUKI, Yoshihisa

Inventor： HADARI, Yaron ,  MANDEL-BAUSCH, Elizabeth, M. ,  RADKE, Susanne ,  SCHLESSINGER, Joseph ,  SUZUKI, Yoshihisa

IPC: A61K39/395 ,  C07K16/32 ,  C07K16/46 ,  C12N15/13 ,  A61P35/00 ,  A61P29/00 ,  A61P35/02 ,  C12N15/63 ,  C12N5/16 ,  C12N5/10 ,  C12N5/09 ,  C12P21/02 ,  C12N1/21 ,  C12N1/19 ,  C12N1/13

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C12N9/2497 ,  G01N33/573 ,  G01N33/6854 ,  G01N2333/912

Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein.

Abstract translation: 在本文中，一方面，是免疫特异性结合包含第四和/或第五细胞外Ig样结构域（即D4和/或D5结构域）的人类KIT抗原的抗体，包含编码这种抗体的核苷酸序列的多核苷酸，以及 表达载体和用于产生此类抗体的宿主细胞。 抗体可以抑制KIT活性，例如配体诱导的受体磷酸化。 本文还提供包含特异性结合KIT抗原的抗体的试剂盒和药物组合物，以及使用本文所述抗体诊断或治疗KIT介导的病症或疾病的方法以及诊断KIT介导的病症或疾病的方法。